Taysha Gene Therapies, Inc. ( (TSHA) ) has released its Q4 earnings. Here is a breakdown of the information Taysha Gene Therapies, Inc. presented to its investors.
Taysha Gene Therapies, Inc. is a clinical-stage biotechnology company specializing in adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system, with a focus on Rett syndrome.
In its latest earnings report, Taysha Gene Therapies announced the completion of dosing in Part A of its REVEAL trials for TSHA-102, a gene therapy candidate for Rett syndrome. The company highlighted the therapy’s tolerability across different age groups and its ongoing discussions with the FDA regarding the regulatory pathway for TSHA-102.
Key financial metrics from the report include a net loss of $89.3 million for 2024, an improvement from the previous year’s loss of $111.6 million. Research and development expenses increased to $66 million, reflecting the company’s focus on advancing its clinical trials. Taysha ended the year with $139 million in cash and cash equivalents, providing a solid financial base for future operations.
Looking ahead, Taysha Gene Therapies plans to update stakeholders on the pivotal trial design for TSHA-102 in the first half of 2025. The company remains optimistic about the potential of TSHA-102 to offer meaningful therapeutic benefits to patients with Rett syndrome, as it continues to engage with regulatory authorities and advance its clinical programs.